Published in World J Gastroenterol on September 21, 2005
Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency. Core Evid (2012) 0.78
Prospective evaluation of quality of life in patients with Zollinger-Ellison syndrome. Dig Dis Sci (2010) 0.75
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Genetic aspects of adenomatosis of endocrine glands. Am J Med (1954) 4.60
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med (1992) 4.33
Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature (1988) 3.96
Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med (1999) 3.21
THE ZOLLINGER-ELLISON SYNDROME: RE-APPRAISAL AND EVALUATION OF 260 REGISTERED CASES. Ann Surg (1964) 2.73
Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med (1992) 2.70
Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg (1996) 2.69
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14
Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med (1990) 2.12
Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology (1995) 2.03
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet (1997) 1.90
Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) (2000) 1.88
Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (1997) 1.82
Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol (2000) 1.79
Zollinger-Ellison syndrome. Gastroenterology (1973) 1.79
Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med (1989) 1.78
Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet (1997) 1.70
Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology (2002) 1.62
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol (2001) 1.60
Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol (2000) 1.59
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol (1999) 1.59
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53
Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol (1998) 1.48
Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med (1983) 1.42
Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) (2004) 1.39
Pancreatic venous sampling and arteriography in localizing insulinomas and gastrinomas: procedure and results in 55 cases. Radiology (1982) 1.37
Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg (1997) 1.29
Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg (1994) 1.21
Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer (2002) 1.16
Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med (1998) 1.15
Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis. Digestion (2003) 1.14
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion (2000) 1.14
Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) (2001) 1.14
Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion (2000) 1.12
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med (2001) 1.10
Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery (1995) 1.10
Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med (1994) 1.08
Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology (1985) 1.07
Molecular genetics of neuroendocrine tumors. Digestion (2000) 1.06
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) (2000) 1.05
Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med (1998) 1.05
Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. AJR Am J Roentgenol (1995) 1.03
Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut (1992) 1.03
Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med (1987) 1.02
Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Aliment Pharmacol Ther (1988) 1.02
The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology (1990) 1.02
Role of selective angiography in the management of patients with Zollinger-Ellison syndrome. Gastroenterology (1987) 1.01
Chemotherapy of endocrine malignancies: a review. Semin Oncol (1987) 1.00
Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology (1992) 0.99
Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg (1993) 0.99
Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion (2000) 0.99
The clinical diagnosis of the Zollinger-Ellison syndrome. Scand J Gastroenterol Suppl (1979) 0.98
Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol (2001) 0.98
Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology (2000) 0.97
Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med (2000) 0.97
Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut (1988) 0.97
Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol (2001) 0.96
Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology (1988) 0.96
The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch Surg (1991) 0.95
The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery (1989) 0.95
Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg (2002) 0.94
Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther (2000) 0.94
Endoscopic ultrasound for localisation of islet cell tumours. Gut (1992) 0.94
Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion (1994) 0.94
Outcome of lymph node involvement in patients with the Zollinger-Ellison syndrome. Ann Surg (1988) 0.93
Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol (2003) 0.93
Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery (1994) 0.92
Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol (2000) 0.90
Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol (1998) 0.89
Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol (2001) 0.88
Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. Regul Pept (1993) 0.86
Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg (1998) 0.86
Morphological, molecular, and prognostic aspects of gastric endocrine tumors. Microsc Res Tech (2000) 0.85
Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology (1991) 0.85
Zollinger-Ellison syndrome: prospective assessment of abdominal US in the localization of gastrinomas. Radiology (1991) 0.84
Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med (1998) 0.84
The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg (1996) 0.84
Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology (1993) 0.83
Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. Am J Med (1984) 0.83
Surgical resection of intracardiac gastrinoma. Ann Thorac Surg (1999) 0.83
The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg (1998) 0.82
Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg (1998) 0.82
Gastrointestinal endocrine tumours. Gastrinoma. Baillieres Clin Gastroenterol (1996) 0.82
Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther (1993) 0.82
Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology (1997) 0.81
Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol (1998) 0.81
Gastrin-dependent inhibitory effects of octreotide on the genesis of gastric ECLomas. Surgery (1992) 0.81
Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. 1955. CA Cancer J Clin (1989) 0.81
Primary cardiac gastrinoma causing Zollinger-Ellison syndrome. Gastroenterology (1997) 0.80
Action of somatostatin analogue (SMS 201-995) on the growth-promoting effect resulting from sustained achlorhydria in rat gastric mucosa, with special reference to endocrine cell behaviour. Eur J Clin Invest (1988) 0.80
A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer. Gastroenterology (2001) 0.80
The Zollinger--Ellison syndrome. Clin Endocrinol Metab (1979) 0.79
A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery (1988) 0.79
Biochemical diagnosis of gastroenteropancreatic endocrine tumors. Minerva Med (2003) 0.79
Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas (1988) 0.77
A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther (1996) 0.77
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology (2007) 2.63
Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol (2009) 2.57
Chronic intestinal pseudo-obstruction. World J Gastroenterol (2008) 2.29
Does acute alcoholic pancreatitis precede the chronic form or is the opposite true? A histological study. J Clin Gastroenterol (2004) 2.28
Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study. Am J Gastroenterol (2013) 2.11
Inflammatory neuropathies of the enteric nervous system. Gastroenterology (2004) 2.02
Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: a prospective study. Scand J Gastroenterol (2009) 1.99
Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol (2010) 1.93
Warm water or oil-assisted colonoscopy: toward simpler examinations? Am J Gastroenterol (2007) 1.77
Enteric neuroplasticity evoked by inflammation. Auton Neurosci (2006) 1.55
Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol (2012) 1.51
Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol (2007) 1.49
Usefulness of serum IgG4 in the diagnosis and follow up of autoimmune pancreatitis: A systematic literature review and meta-analysis. J Gastroenterol Hepatol (2008) 1.44
Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol (2005) 1.42
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol (2011) 1.42
Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol (2011) 1.41
Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol (2005) 1.35
Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol (2002) 1.22
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med (2010) 1.19
Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology (2003) 1.19
Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am (2011) 1.18
The immune system in irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.16
Sedation-risk-free colonoscopy for minimizing the burden of colorectal cancer screening. World J Gastrointest Endosc (2010) 1.15
Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Am J Gastroenterol (2002) 1.12
Consensus guidelines on severe acute pancreatitis. Dig Liver Dis (2015) 1.12
The problems of radiofrequency ablation as an approach for advanced unresectable ductal pancreatic carcinoma. Cancers (Basel) (2010) 1.09
A prospective study on radiofrequency ablation locally advanced pancreatic cancer. Hepatobiliary Pancreat Dis Int (2010) 1.09
An update on recurrent acute pancreatitis: data from five European countries. Am J Gastroenterol (2002) 1.09
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. Clin Nucl Med (2011) 1.08
Chronic intestinal pseudo-obstruction. Best Pract Res Clin Gastroenterol (2007) 1.03
Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis (2010) 1.02
Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med (2010) 1.02
Effect of secretin on serum pancreatic enzymes and on the Wirsung duct in chronic nonpathological pancreatic hyperenzymemia. Pancreatology (2003) 1.01
Quality of life and clinical indicators for chronic pancreatitis patients in a 2-year follow-up study. Pancreas (2007) 1.00
Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep (2011) 0.99
Dyspeptic symptoms in primary care. An observational study in general practice. Eur J Gastroenterol Hepatol (2002) 0.99
Mechanisms involved in the onset of post-ERCP pancreatitis. JOP (2002) 0.99
Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol (2012) 0.99
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging (2008) 0.99
Mutations of the CFTR gene in pancreatic disease. Pancreas (2003) 0.98
Is troponin T a useful marker of myocardial damage in acute pancreatitis? A prospective time course study. Dig Liver Dis (2012) 0.97
Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology (2011) 0.96
Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis (2012) 0.95
Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas (2011) 0.95
Exocrine pancreatic function assessed by secretin cholangio-Wirsung magnetic resonance imaging. Hepatobiliary Pancreat Dis Int (2008) 0.94
Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. Pancreas (2010) 0.93
Is the pancreas affected in patients with septic shock?--a prospective study. Hepatobiliary Pancreat Dis Int (2011) 0.92
Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Am J Pathol (2012) 0.92
Lung injury in acute pancreatitis. JOP (2009) 0.91
Hydrogen sulfide, nitric oxide and a molecular mass 66 u substance in the exhaled breath of chronic pancreatitis patients. Pancreatology (2007) 0.91
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2010) 0.91
Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr (2009) 0.91
Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology (2010) 0.91
Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature. Updates Surg (2010) 0.91
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging (2012) 0.91
Cystic dystrophy of the duodenal wall is not always associated with chronic pancreatitis. World J Gastroenterol (2011) 0.91
Solid serous microcystic tumor of the pancreas. JOP (2008) 0.90
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin. Antiviral Res (2010) 0.90
Spontaneous Cholecystocutaneous Fistula. Case Rep Gastroenterol (2010) 0.90
Fecal calprotectin levels in patients with colonic polyposis. Dig Dis Sci (2007) 0.89
Tyrosine kinase inhibitors and acute pancreatitis. JOP (2010) 0.89
IgG4 as a serological marker of autoimmune pancreatitis: the latest news. JOP (2004) 0.88
Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues. Dig Dis (2007) 0.88
Immune-manipulation of the inflammatory response in acute pancreatitis. What can be expected? JOP (2004) 0.87
A search for acute necrotic pancreatitis in early stages of alcoholic chronic pancreatitis. J Clin Gastroenterol (2006) 0.87
Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation. World J Gastroenterol (2009) 0.87
Adult coeliac disease diagnosed by endoscopic biopsies in the duodenal bulb. Eur J Gastroenterol Hepatol (2005) 0.86
Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology (2006) 0.86
Assessment of severity of acute pancreatitis: a comparison between old and most recent modalities used to evaluate this perennial problem. World J Gastroenterol (1999) 0.86
ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep (2013) 0.86
Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol (2010) 0.86
Chronic pancreatitis: assessing the quality of life. JOP (2005) 0.86
Enteric neuropathology of congenital intestinal obstruction: A case report. World J Gastroenterol (2006) 0.86
BAG3 is a novel serum biomarker for pancreatic adenocarcinomas. Am J Gastroenterol (2013) 0.86
PET/CT with 68Gallium-DOTA-peptides in NET: an overview. Eur J Radiol (2010) 0.86
Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas (2014) 0.85
Routine duodenal biopsies: is it time to change our minds? Gastrointest Endosc (2004) 0.85